Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2020

View Archived Issues

First-in-human study tests BI-764524 in diabetic macular ischemia

Akeso begins first-in-human study of AK-120 for atopic dermatitis

JS InnoPharm evaluates JSI-1187 for advanced solid tumors with MAPK pathway mutations

Placental attachment theory

CH-7233163: an EGFR inhibitor active against osimertinib-resistant EGFR-T790M/C797S mutations

Novel CTH-004 CAR T cells for the treatment of ovarian cancer

Machine learning, GWAS divide and conquer PCOS

TN1-006: a gene therapy-mediated cardiac reprogramming candidate with potential for MI treatment

Bayer, Deutsches Krebsforschungszentrum present new MAP4K1 inhibitors

CECSi cells show promising preclinical results for the treatment of bullous keratopathy

New gamma-secretase inhibitors identified at Roche

Lynk Pharmaceuticals patents Janus kinase inhibitors

Dual CACNA2D1/mu-opioid receptor ligands discovered at Esteve

Emerald Health Biotechnology Espana identifies monoglyceride lipase inhibitors

FDA approves IND for phase II study of antroquinonol in patients with COVID-19

Phase I study of DS-1062 expanded to include patients with TNBC

Menarini plans phase Ib/II study of MEN-1611 in metastatic colorectal cancer

FDA clears initiation of phase III trial of siltuximab for COVID-19-associated ARDS

Early positive data for BNT-162b1 vaccine candidate against SARS-CoV-2

Recruitment starts in phase II study of DUR-928 in COVID-19 with acute liver or kidney injury

European Commission approves canagliflozin label update

Promising efficacy of SJP-1602 in models of TNBC

RO-7297089 begins first-in-human study for relapsed or refractory multiple myeloma

Chinese phase I study evaluates TQB-3558 for solid tumors

European Commission approves Janssen's Ebola vaccine regimen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...